BioRadar Blog
Biotech trading insights, PDUFA analysis, and market intelligence.
Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 28–Jul 5, 2026)
Here’s what’s on the biotech calendar for June 28–July 5: 2 FDA decision dates, 15 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date…
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 21–Jun 28, 2026)
Here’s what’s on the biotech calendar for June 21–June 28: 0 FDA decision dates, 0 trial catalysts, and 0 earnings reports from tracked companies. 📡 Run-up Radar Highlights Stocks entering…
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 14–Jun 21, 2026)
OSTX dominates this week’s catalyst calendar with three trial readouts spanning solid tumors and hematologic malignancies, including a promising CAR-T study in relapsed AML. The week offers a lighter schedule…
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 10–Jun 17, 2026)
This week brings a focused slate of clinical readouts, with Osteoxenon (OSTX) commanding attention through two distinct oncology programs. The most intriguing catalyst may be OSTX’s CD33 CAR-T data in…
Read article →Biotech’s Biggest Statistical Fallacy: Why Comparing to Historical Data is an Investor’s Worst Trap
Historical survival data can be useful context — but it becomes dangerous when investors treat it as the control arm their trial will actually face. Biotech investing is notoriously binary—a…
Read article →Biotech Conference Season 2026: Which Events Move Stocks the Most
Biotech conferences are where companies present clinical data for the first time, announce partnerships, and reveal pipeline updates. For traders, conference season creates some of the most predictable volatility windows…
Read article →Insider Trading in Biotech: What SEC Form 4 Filings Really Tell You
When a biotech CEO buys shares of their own company with personal money before a major catalyst, it is one of the strongest bullish signals in the entire market. Insider…
Read article →Understanding Drug Pipelines: How to Evaluate a Biotech Company Like an Analyst
A biotech company is only as valuable as its drug pipeline. Unlike traditional companies valued on revenue and earnings, biotech valuations are driven by the probability-weighted value of drugs in…
Read article →Short Squeeze Setups in Biotech: How to Spot Them Before They Explode
Biotech short squeezes are among the most explosive moves in the stock market. When a heavily shorted stock gets a positive catalyst — FDA approval, strong trial data, or a…
Read article →How to Read Biotech Cash Runway: The #1 Signal That Predicts Dilution
In biotech investing, cash runway is the single most important metric that separates winners from dilution traps. Unlike revenue-generating companies, most biotech firms burn cash every quarter while waiting for…
Read article →